BIOBASE to Coordinate EU-backed Project to Develop Technology for Studying Mechanisms of Disease.WOLFENBUTTEL, Germany & BEVERLY, Mass. -- BIOBASE, a leading provider of knowledge solutions for the life sciences industry, announced today that they have received a European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community research contract to develop innovative technology to analyze complex disease mechanisms. The three-year, 3 million Euro project, called Net2Drug, will be coordinated by BIOBASE and developed as a collaboration with several international participants. The project's goal is to create a sophisticated "toolbox" integrating cutting edge bioinformatics, chemoinformatics, and experimental methods to identify potential therapeutic targets. "Understanding the mechanism of disease is the key to rationalizing drug development. Net2Drug will provide a knowledge-based approach for identifying critical components in the gene regulatory network A gene regulatory network (also called a GRN or genetic regulatory network) is a collection of DNA segments in a cell which interact with each other (indirectly through their RNA and protein expression products) and with other substances in the cell, thereby that accounts for a specific disease," explains Prof. Edgar Wingender, President and CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. of BIOBASE, "This approach will enable researchers to confidently select promising drug targets and efficiently identify chemical compounds directed against these targets". Dr. Alexander Kel, Senior Vice President Research & Development at BIOBASE and project coordinator adds: "Net2Drug will integrate different 'omics' datasets such as proteomics and genomics into cohesive networks to facilitate comprehensive understanding of complex human pathologies. Proof-of-concept will be given by applying our technology on certain tumor types, in particular breast cancer." The International Net2Drug Consortium The Net2Drug consortium includes BIOBASE GmbH (Germany) as coordinator, Progenika Biopharma S.L. (Spain), University of Helsinki The University of Helsinki is not to be confused with the Helsinki University of Technology. The University of Helsinki (Finnish: Helsingin yliopisto, Swedish: Helsingfors universitet (Finland), Fraunhofer Institute fur Toxikologie und Experimentelle Medizin (Germany), University of Gottingen/Medical School (Germany), Institute of Systems Biology, Ltd, Novosibirsk (Russia), Institute of Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Chemistry of Russian Academy of Medical Sciences, Moscow (Russia) Microbiology and Tumor Biology Center (MTC mtc - A Modula-2 to C translator. ftp://rusmv1.rus.uni-stuttgart.de/soft/Unixtools/compilerbau/mtc.tar.Z. ), Karolinska Institute (Sweden), and the CNR-ITB Institute of Biomedical Technologies (Italy). The European Union's Sixth Framework Programme The Sixth Framework Programme (abbreviated FP6) was the Framework Programme for Research and Technological Development from 2002 till 2006 set up by the European Union (EU) in order to fund and promote European research and technological development. (FP6) Life Sciences, Genomics and Biotechnology for Health is one of seven top priorities of the European Union's Sixth Framework Programme (FP6). The FP6 objective is to help Europe take advantage of unprecedented opportunities for generating new knowledge and translating it into applications that enhance human health. To this end, fundamental and applied research is supported, with an emphasis on integrated, multidisciplinary, and coordinated efforts addressing the present fragmentation of European research and increase the competitiveness of the European biotechnology industry. The indicative budget is EUR EUR In currencies, this is the abbreviation for the Euro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 2514 million for the period 2002-2006, including up to EUR 475 million for cancer-related research. About BIOBASE GmbH BIOBASE (www.biobase-international.com), based in Wolfenbuttel (Germany), with branch offices in Beverly, MA (USA) and Bangalore (India) is the leading provider of expertly-curated biological databases and sophisticated software tools. The BIOBASE Knowledge Library includes but is not limited to the TRANSFAC([R]), TRANSPATH([R]), YPD YPD Yeast Peptone Dextrose (media for growing yeast) YPD Young People's Division YPD Floating Pile Driver (Non Self-Propelled) YPD Yonkers Police Department (TM) and HumanPSD(TM) databases. In combination, the systems biology analysis platform ExPlain[TM] offers the identification of molecular networks and key molecules critical to discovery research. BIOBASE also provides a growing portfolio of databases of third parties such as BRENDA([R]) and HGMD HGMD Human Gene Mutation Database HGMD Hybrid Genetic Multiuser Detector ([R]). Our customers include the leading academic and research institutions around the world. For more information, please visit our website at www.biobase-international.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion